CART-BCMA cohort patient characteristics
| Characteristic . | RMP (n = 24) . | Non-RMP (n = 116) . | P value . |
|---|---|---|---|
| Patient age, median (IQR), y | 62 (57-66) | 66 (61-70) | .02 |
| Male | 11 (46) | 68 (59) | .36 |
| Product infused | |||
| cilta-cel | 13 (54) | 58 (50) | .81 |
| ide-cel | 11 (46) | 58 (50) | |
| Out-of-specification products | 1 (4.2) | 5 (4.3) | .99 |
| R-ISS at diagnosis >1 | 17/20 (85) | 58/77 (75) | .54 |
| Median previous lines of therapy (IQR) | 5 (5-7) | 6 (5-8) | .04 |
| Previous autologous SCT | 22 (92) | 100 (86) | .69 |
| Previous allogeneic SCT | 0 (0) | 5 (4.3) | .67 |
| Triple-class refractory∗ | 19 (79) | 96 (83) | .90 |
| Penta-refractory disease† | 5 (21) | 39 (34) | .31 |
| ECOG at infusion <2 | 22 (92) | 86 (74) | .11 |
| High-risk cytogenetics at diagnosis‡ | 7/17 (41) | 42/105 (40) | .99 |
| Extramedullary disease | 7 (29) | 25 (22) | .42 |
| Bridging therapy | 23 (96) | 109 (94) | .99 |
| Lymphodepletion | |||
| Flu/Cy | 23 (96) | 100 (87) | .53 |
| Cy-based | 1 (4) | 13 (11) | |
| Bendamustine | 0 | 1 (0.9) | |
| M-spike at CART, median (IQR), g/dL | 0.9 (0-1.7) | 0.25 (0-1.3) | .15 |
| Differential light chain at CART, median (IQR), mg/L | 245 (35-661) | 91 (20-425) | .20 |
| Characteristic . | RMP (n = 24) . | Non-RMP (n = 116) . | P value . |
|---|---|---|---|
| Patient age, median (IQR), y | 62 (57-66) | 66 (61-70) | .02 |
| Male | 11 (46) | 68 (59) | .36 |
| Product infused | |||
| cilta-cel | 13 (54) | 58 (50) | .81 |
| ide-cel | 11 (46) | 58 (50) | |
| Out-of-specification products | 1 (4.2) | 5 (4.3) | .99 |
| R-ISS at diagnosis >1 | 17/20 (85) | 58/77 (75) | .54 |
| Median previous lines of therapy (IQR) | 5 (5-7) | 6 (5-8) | .04 |
| Previous autologous SCT | 22 (92) | 100 (86) | .69 |
| Previous allogeneic SCT | 0 (0) | 5 (4.3) | .67 |
| Triple-class refractory∗ | 19 (79) | 96 (83) | .90 |
| Penta-refractory disease† | 5 (21) | 39 (34) | .31 |
| ECOG at infusion <2 | 22 (92) | 86 (74) | .11 |
| High-risk cytogenetics at diagnosis‡ | 7/17 (41) | 42/105 (40) | .99 |
| Extramedullary disease | 7 (29) | 25 (22) | .42 |
| Bridging therapy | 23 (96) | 109 (94) | .99 |
| Lymphodepletion | |||
| Flu/Cy | 23 (96) | 100 (87) | .53 |
| Cy-based | 1 (4) | 13 (11) | |
| Bendamustine | 0 | 1 (0.9) | |
| M-spike at CART, median (IQR), g/dL | 0.9 (0-1.7) | 0.25 (0-1.3) | .15 |
| Differential light chain at CART, median (IQR), mg/L | 245 (35-661) | 91 (20-425) | .20 |
Data are presented as n (%) unless otherwise specified. Bold values are statistically significant (P < .05).
Cy, cyclophosphamide; ECOG, Eastern Cooperative Oncology Group; Flu, fludarabine; R-ISS, Revised International Staging System; SCT, stem cell transplantation.
Triple-class–refractory disease was defined as disease refractory to an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.
Penta-refractory disease was defined as a disease refractory to lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab.
High-risk cytogenetic abnormalities included del(17p), t(4;14), t(14;20), t(14;16), and gain/amplification of 1q.